Research and clinical experience suggest that IV NAD+ produces a sharp but short-lived spike in plasma levels that does not reliably translate to intracellular increases, which is where the therapeutic effect actually happens
DallOlmo, L., et al
Incretin-based therapies are being rapidly explored for T2DM treatment, including GLP-1 analogs and receptor agonists, and dipeptidyl peptidase-4 inhibitors (DPP-4i)
Specifically, a study of zibotentan, a highly selective endothelin A ERA, in combination with dapagliflozin in participants with type 2 diabetes (NCT05570305) is currently underway, with similar phase 2 trials in type 1 diabetes being proposed
AMP-activated protein kinase attenuates nitric oxide-induced -cell death
These products are potentially unsafe and ineffective, and might contain unknown harmful ingredients or contaminants. Those who start using skin lightening say they invariably stay with the practice